Rare diseases
Investigational molecules
Locations
293 conditions with trials, the busiest first
1 664 trials across Europe, recruiting first
Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis
CzechiaStudy of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment
AustriaLong-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031
CzechiaStudy of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis
BelgiumStudy of tildrakizumab to treat patients with chronic spontaneous urticaria who did not respond to previous treatments
GermanyStudy of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment
BelgiumStudy of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness
GermanyStudy of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab
FranceLong-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease
BelgiumStudy of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis
BelgiumStudy of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease
BulgariaStudy of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness
GreeceThe therapies tested most often in Immune system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
